Evaluating the Quality of Selected Commercial Probiotic Products, Both Dietary Supplements and Foods for Special Medical Purposes.

2026-01-20
Foods (Basel, Switzerland) 15(2)

PubMed: 41596971
DOI: 10.3390/foods15020373

Study Design

Population: Fifteen commercial probiotic products available on the Polish market, including both dietary supplements and foods for special medical purposes
Methods: Quantitative and qualitative characteristics were evaluated; viable microorganism counts were determined using the traditional culture-based plate count method and by flow cytometry for selected products; species identification was performed using MALDI-TOF MS and qPCR; microbiological purity testing was conducted to confirm the absence of pathogenic bacteria

Probiotics are live microorganisms that provide health benefits when administered in adequate amounts. Due to the increasing popularity of probiotic supplements, concerns have arisen regarding their quality, microbial composition, and safety. This study aimed to evaluate the quantitative and qualitative characteristics of the selected probiotics available on the Polish market, including both dietary supplements and foods for special medical purposes, and to compare the obtained results with the information provided on the product labels. Fifteen commercial probiotic products were analysed. Viable microorganism counts were determined using the traditional culture-based plate count method and by flow cytometry for selected products. Species identification was performed using MALDI-TOF MS and qPCR, whereas microbiological purity testing was conducted to confirm the absence of pathogenic bacteria. Significant differences were observed between the declared and experimentally determined numbers of viable microorganisms. Only a few products maintained bacterial counts consistent with label claims, while most contained considerably low viable cells. Flow cytometry revealed higher viable cell counts than plate counting, indicating the presence of viable but non-culturable bacteria. The declared species composition of the strains was mostly confirmed, although in several cases, undeclared probiotic microorganisms were identified. All tested products were free from pathogens. The study indicates significant discrepancies in the quality of probiotic supplements available on the Polish market. From a consumer perspective, these findings highlight the importance of verifying probiotic quality and suggest that not all commercial products may guarantee the full range of claimed health benefits. The implementation of standardised analytical procedures and enhanced quality control measures is therefore essential to ensure the product safety, strain authenticity, and reliability of health-related claims.

Research Insights

Supplement	Dose	Health Outcome	Effect Type	Effect Size	Source
Bifidobacterium infantis BI02	—	No Human Health Outcome Reported	Neutral	Small	View source The abstract evaluates the quality, microbial composition, and safety of commercial probiotic products and does not report any health outcomes from consuming Bifidobacterium infantis BI02.